Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield(Revolution Medicines (United States)), Elena S. Koltun(Revolution Medicines (United States)), Mallika Singh(Revolution Medicines (United States)), Harshit Shah(North Dakota State University), Nicole Nasholm(Revolution Medicines (United States)), Abby Marquez(Revolution Medicines (United States)), Chiara Ambrogio(Dana-Farber Cancer Institute), Lo Lai(Georgia State University), Adrian L. Gill(AstraZeneca (Sweden)), Elsa Quintana(Revolution Medicines (United States)), James Evans(Temple College), Grace Goodhart(University of Cincinnati), Andrew M. Waters(University of North Carolina at Chapel Hill), Julien Dilly(Massachusetts Institute of Technology), Yingyun Wang(Revolution Medicines (United States)), Kyle J. Seamon(Revolution Medicines (United States)), John E. Knox(Revolution Medicines (United States)), Nuntana Dinglasan(Revolution Medicines (United States)), Anthony Salvador(Revolution Medicines (United States)), Nataliya Tovbis Shifrin(Revolution Medicines (United States)), Jennifer A. Roth(Broad Institute), Aidan C.A. Tomlinson(Revolution Medicines (United States)), Piro Lito(Memorial Sloan Kettering Cancer Center), Feng Hu(Memorial Sloan Kettering Cancer Center), David Santamarı́a(Centro de Investigación del Cáncer), Channing J. Der(University of North Carolina at Chapel Hill), Matthew G. Rees(Broad Institute), Stephanie Chang, Lingyan Jiang(Hainan University), Antonio Cuevas-Navarro(Memorial Sloan Kettering Cancer Center), Cristina Blaj(Revolution Medicines (United States)), Jim Cregg(Revolution Medicines (United States)), Andrew J. Aguirre(Broad Institute), Yevgeniy Gindin(Revolution Medicines (United States)), Ethan Ahler(Revolution Medicines (United States)), Alessia Mira(University of Turin), Bianca J. Lee(Revolution Medicines (United States)), Enrico Patrucco(University of Turin), Nilufar Montazer(Revolution Medicines (United States)), Tamar Bar Ziv(Revolution Medicines (United States)), Yang Liu(Sun Yat-sen University), Anqi Chen(Macau University of Science and Technology), Jingjing Jiang(Revolution Medicines (United States)), Zhengping Wang(Shandong University), Dylan Parsons(Revolution Medicines (United States)), Oliver Lai(Revolution Medicines (United States)), Jennifer E. Klomp(Michigan State University), Shurui Cai(The Ohio State University), Melissa M. Ronan(Broad Institute), Anthony N. Milin(Revolution Medicines (United States))
Cited by 319
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Efficient tumour formation by single human melanoma cells
|Nature|2008|1.8k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
|Genes & Development|2003|1k
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
|Nature Cancer|2020|880